Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 302

Sort by

Sort Order Select

Journal Articles

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Blood (2024) 144 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2024-211012

Published: 2024

Journal Articles

Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

Blood (2024) 144 (Supplement 1): 3760.

https://doi.org/10.1182/blood-2024-201712

Published: 2024

Journal Articles

Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy

Blood (2024) 144 (Supplement 1): 1607.

https://doi.org/10.1182/blood-2024-200927

Published: 2024

Journal Articles

Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial

Charlotte Pawlyn, Faith E Davies, Gordon Cook, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Catherine Olivier, Anna Hockaday, John R Jones, Martin F Kaiser, Matthew W. Jenner, Walter Martin Gregory, Ruth M de Tute, Roger G Owen, Mark Drayson, David A. Cairns, Gareth Morgan, Graham Jackson

Blood (2024) 144 (Supplement 1): 1987.

https://doi.org/10.1182/blood-2024-205788

Published: 2024

Journal Articles

A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation

Blood (2024) 144 (Supplement 1): 857.

https://doi.org/10.1182/blood-2024-210654

Published: 2024

Journal Articles

Characterization and Comparative Outcomes of Younger Multiple Myeloma Patients

Andrea Tufano-Sugarman, Shahidul Islam, Faith E Davies, Gareth Morgan, David Kaminetzky, Oscar B Lahoud, Marc J Braunstein

Blood (2024) 144 (Supplement 1): 5155.

https://doi.org/10.1182/blood-2024-211737

Published: 2024

Journal Articles

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Graham Jackson, Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, David A. Cairns, Gareth Morgan

Blood (2024) 144 (Supplement 1): 3375.

https://doi.org/10.1182/blood-2024-205871

Published: 2024

Journal Articles

Bone Marrow Fibroblasts at the Single-Cell Resolution Level in Multiple Myeloma

Jason I. Avigan, Dylan C Gagler, Hussein Ghamlouch, Patrick Blaney, Di Zhang, Faith E Davies, Gareth Morgan

Blood (2024) 144 (Supplement 1): 4636.

https://doi.org/10.1182/blood-2024-194277

Published: 2024

Journal Articles

Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients

Charlotte Pawlyn, Faith E Davies, Martin F Kaiser, Ruth M de Tute, Heather McIntyre, Jeanine Richards, Sharon Jackson, Elizabeth Hodson, Anna Hockaday, Catherine Olivier, John R Jones, Matthew W. Jenner, Gordon Cook, Walter Martin Gregory, Mark Drayson, Roger G Owen, Gareth Morgan, David A. Cairns, Graham Jackson

Blood (2024) 144 (Supplement 1): 771.

https://doi.org/10.1182/blood-2024-208255

Published: 2024

Journal Articles

Identification of Transcriptional Targets of NSD2 and the Underlying Regulatory Mechanism in t(4;14) Multiple Myeloma Cells Using the Slam-Seq and d-TAG Technologies

Yubao Wang, Sanxiong Liu, Hussein Ghamlouch, Faith E Davies, Gareth Morgan

Blood (2024) 144 (Supplement 1): 4122.

https://doi.org/10.1182/blood-2024-205654

Published: 2024

Journal Articles

Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry

Kylee H Maclachlan, Marios Papadimitriou, Patrick Blaney, Tala Shekarkhand, Timothy R. Chu, Alexandra Maria Poos, Elizabeth Brown, Antje Hoering, Benjamin Diamond, Bachisio Ziccheddu, Marc S. Raab, Niels Weinhold, Ola Landgren, Faith E Davies, Alexander M. Lesokhin, Saad Z. Usmani, Francesco Maura, Gareth Morgan

Blood (2024) 144 (Supplement 1): 766.

https://doi.org/10.1182/blood-2024-203675

Published: 2024

Journal Articles

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Blood (2023) 142 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2023-190473

Published: 2023

Journal Articles

Young and Distinct: Clinical Characteristics and Outcomes of Patients 50 or Younger with Multiple Myeloma

Andrea Tufano-Sugarman, Shahidul Islam, Faith E. Davies, Gareth J. Morgan, David Kaminetzky, Marc Braunstein

Blood (2023) 142 (Supplement 1): 6684.

https://doi.org/10.1182/blood-2023-182954

Published: 2023

Journal Articles

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Beth Gordon, Lindsay Fogel, Gaurav Varma, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Xiaoyi Chen, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S. Siegel, Gareth J. Morgan, Ruben Niesvizky, Noa Biran, Faith E. Davies

Blood (2023) 142 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2023-181304

Published: 2023

Journal Articles

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 874.

https://doi.org/10.1182/blood-2023-186802

Published: 2023

Journal Articles

Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

Nathan Beals, Craig Ramirez, Andy Hauser, Faith E. Davies, Dafna Bar-Sagi, Gareth J. Morgan

Blood (2023) 142 (Supplement 1): 54.

https://doi.org/10.1182/blood-2023-186114

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Molly Reed, David Allan Cairns, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin F. Kaiser, Catherine Olivier, Roger Owen, Kevin Boyd, Gordon Cook, Gareth J. Morgan, Graham Jackson, Mark Drayson, John R Jones

Blood (2023) 142 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2023-181939

Published: 2023

Journal Articles

The Cellular Impact, Immediate Targets and Mechanism of Action of NSD2 in t(4;14) Multiple Myeloma

Yubao Wang, Sanxiong Liu, Hussein Ghamlouch, Eileen Boyle, Faith E. Davies, Gareth J. Morgan

Blood (2023) 142 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2023-189012

Published: 2023

Journal Articles

Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development

Hussein Ghamlouch, Dylan Gagler, Patrick Blaney, Eileen Boyle, Yubao Wang, Liming Hou, Ola Landgren, Francesco Maura, Aristotelis Tsirigos, Gareth J. Morgan, Faith E. Davies

Blood (2023) 142 (Supplement 1): 332.

https://doi.org/10.1182/blood-2023-182968

Published: 2023

NARROW

Mutationally Enriched Regions of the Non-Coding Genome Harbor Functionally Impactful Mutations That Dysregulate Key Genes Involved in Multiple Myeloma Pathogenesis

Real-World Characteristics and Treatment Patterns of Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) As Front-Line Treatment: Results from a Multicenter Chart Review Study

Clonal Evolution of Lymphoid Malignancies Following the Mutagenic Impact of Radiotherapy

Optimising the Duration of Therapy for Newly Diagnosed Transplant Ineligible Patients - Analysis of Long Term Follow up Data from the UK MRA Myeloma XI Trial

A Multiomic Analysis of Waldenstrom's Macroglobulinemia Identifies Three Subtypes of Disease Based on Impaired Plasma Cell Differentiation

Characterization and Comparative Outcomes of Younger Multiple Myeloma Patients

MRD and Molecular Risk Status Help to Define Optimal Maintenance Delivery Strategies after ASCT: Long Term Outcomes of the UK MRA Myeloma XI Trial Comparing Lenalidomide to Observation

Bone Marrow Fibroblasts at the Single-Cell Resolution Level in Multiple Myeloma

Final Analysis of the Randomised UK MRA Myeloma XI+ Trial Examining Krdc (carfilzomib, lenalidomide, dexamethasone and cyclophosphamide) As Induction Therapy for Newly Diagnosed Multiple Myeloma Patients

Identification of Transcriptional Targets of NSD2 and the Underlying Regulatory Mechanism in t(4;14) Multiple Myeloma Cells Using the Slam-Seq and d-TAG Technologies

Whole Genome Sequencing Reveals Lower Apobec-Mutational Activity in Multiple Myeloma Patients with African Ancestry Compared with Those Having European Ancestry

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Young and Distinct: Clinical Characteristics and Outcomes of Patients 50 or Younger with Multiple Myeloma

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

The Cellular Impact, Immediate Targets and Mechanism of Action of NSD2 in t(4;14) Multiple Myeloma

Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only